Design Therapeutics, Inc.
DSGN Nasdaq
SEC CIK 1807120
Follow Design Therapeutics
Weekly email: filings, results
Revenue, last quarter
$0
Net income
−$20.3M
−19.4% vs same quarter last year
EPS, diluted
−$0.32
−6.7% vs same quarter last year
Operating cash flow
−$15.4M
−37.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $0 | −$69.8M |
| FY24 | $0 | −$49.6M |
| FY23 | - | −$66.9M |
| FY22 | - | −$63.3M |
| FY21 | - | −$35.5M |
| FY20 | $226K | −$8.3M |
| FY19 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$54.6M |
| FY24 | −$43.4M |
| FY23 | −$58.8M |
| FY22 | −$52.2M |
| FY21 | −$30.9M |
| FY20 | −$8.7M |
| FY19 | - |